Related Experiment Video
Updated: May 26, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Anti-inflammatory withanolides from Physalis minima and their therapeutic potential against ulcerative colitis in
Guozhu Su1, Lisha Chai1, Yu Chen2
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Abstract:
Eleven undescribed withanolides, phyminimolides I-XI (1-11), along with eight known derivatives (12-19), were isolated from the whole plant of Physalis minima Linn. Their structures were elucidated by extensive spectroscopic methods, including 1D-NMR, 2D-NMR, HRESIMS, IR, experimental electronic circular dichroism, quantum chemical calculation, and X-ray crystallography. The anti-inflammatory potential of these compounds was assessed in vitro via their capacity to inhibit nuclear factor kappa-B signaling in lipopolysaccharide-stimulated 293T/NF-κB-luciferase reporter cells, revealing IC50 values of 9.95, 3.15, 1.16, 9.73, and 11.74 μM for compounds 4-6, 13, and 15, respectively. Notably, compounds 4 and 13 also demonstrated inhibitory effects on interleukin-6 pathway activation, with IC50 values of 1.61 and 7.56 μM, further evidencing their anti-inflammatory mechanism. In vivo assessment using dextran sulfate sodium-induced mice model of ulcerative colitis confirmed the translational efficacy of these findings. Compound 15, administered at a dose of 25 mg/kg, significantly ameliorated disease symptoms, as evidenced by a decreased Disease Activity Index score (P < 0.05).
More Related Videos
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

